Table 3.

Multivariable multinomial regression models of prescription contraceptive prevalence among U.S. women 20−49 years with opioid use disorder, by medications for opioid use disorder prescription status and insurance type, IBM Watson MarketScan 2018

		Long-acting reversible contraception	Short-acting hormonal contraception	Female sterilization	No prescription contraception or female sterilizationb
		aOR (95% CI)	aOR (95% CI)	aOR (95% CI)
Commercial Insurance	Prescribed MOUD vs not prescribeda	0.97 (0.79, 1.21)	0.82 (0.67, 1.01)	1.03 (0.68, 1.57)	ref
Medicaid Insurance	Prescribed MOUD vs not prescribedc	1.10 (0.87, 1.40)	1.05 (0.81, 1.38)	1.33 (1.06, 1.67)	ref

MOUD, medications for opioid use disorder; aOR, adjusted odds ratio; ref, reference.

Opioid use disorder is defined by diagnostic codes, procedural codes and outpatient prescriptions in claims data (Appendix)

Assignment of contraceptive method was by most effective method

Diagnostic codes, procedural codes and outpatient prescription drug claims were used to define contraception use (Appendix)

^aadjusted for age and selected medical conditions identified through diagnosis codes (Appendix): diabetes, hypertension, epilepsy, breast cancer, endometrial cancer, ovarian cancer, tuberculosis, sickle cell disease, systemic lupus erythematosus, cirrhosis, thrombogenic mutations, schistosomiasis with fibrosis of liver, liver cancer, gestational trophoblastic disease, ischemic heart disease, valvular heart disease, stroke, transplantation, peripartum cardiomyopathy, bariatric surgery, and migraines (without or without aura).

^badjusted for age, race and medical conditions.

^cadjusted for age